Compare Citius Pharmaceuticals Inc (CTXR) vs Deutsche Bank AG (DB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Deutsche Bank AG — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while Deutsche Bank AG trades at $38.4 (market cap $71.96B). The key difference: Deutsche Bank AG is far larger — about 3596.2× Citius Pharmaceuticals Inc's market cap, and Deutsche Bank AG pays a 3.04% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | DB | |
|---|---|---|
Market Cap | $20.01M | $71.96B |
Sector | Health | Financials |
52-Week High | $1.82 | $40.33 |
52-Week Low | $0.48 | $28.37 |
Enterprise Value | $16.23M | — |
Dividend Yield | — | 3.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Deutsche Bank (DB) trades at $38.27, up 0.55% today, with a bullish technical signal from moving averages. The stock shows a discounted valuation with a P/E of 10.07 and P/B of 0.79. Recent Q2 2026 earnings missed expectations at $0.66 per share versus $0.91, but revenue growth remains solid. The company announced a $1.00 dividend and a new share buyback program, supported by strong capital buffers and its recent designation as a clearing bank for China's renminbi (Reuters, 2026-08-10).
The outlook is mixed; strong operational performance and strategic initiatives like AI dealmaking (CNBC, 2026-07-29) offer upside, but earnings volatility and regulatory scrutiny (Reuters, 2026-07-22) pose risks. Analyst consensus is neutral with 57.58% hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →
